{"title":"Articles of Significant Interest Selected from This Issue by the Editors","authors":"","doi":"10.1128/cvi.00257-17","DOIUrl":null,"url":null,"abstract":"The human hepatitis B virus polymerase (hPOL) is central to viral replication and therefore a therapeutic target. The inability to produce large quantities of recombinant hPOL has impeded structural studies of this protein. Vörös et al. (p. 2584 –2599) developed procedures to express high yields of soluble, active recombinant hPOL constructs in Escherichia coli. This advance enabled the first structural and biophysical characterizations of hPOL. The findings provide new insights into hPOL structure and function and may accelerate drug discovery for hepatitis B virus.","PeriodicalId":10271,"journal":{"name":"Clinical and Vaccine Immunology","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2017-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and Vaccine Immunology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1128/cvi.00257-17","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Biochemistry, Genetics and Molecular Biology","Score":null,"Total":0}
引用次数: 0
Abstract
The human hepatitis B virus polymerase (hPOL) is central to viral replication and therefore a therapeutic target. The inability to produce large quantities of recombinant hPOL has impeded structural studies of this protein. Vörös et al. (p. 2584 –2599) developed procedures to express high yields of soluble, active recombinant hPOL constructs in Escherichia coli. This advance enabled the first structural and biophysical characterizations of hPOL. The findings provide new insights into hPOL structure and function and may accelerate drug discovery for hepatitis B virus.
期刊介绍：
Cessation. First launched as Clinical and Diagnostic Laboratory Immunology (CDLI) in 1994, CVI published articles that enhanced the understanding of the immune response in health and disease and after vaccination by showcasing discoveries in clinical, laboratory, and vaccine immunology. CVI was committed to advancing all aspects of vaccine research and immunization, including discovery of new vaccine antigens and vaccine design, development and evaluation of vaccines in animal models and in humans, characterization of immune responses and mechanisms of vaccine action, controlled challenge studies to assess vaccine efficacy, study of vaccine vectors, adjuvants, and immunomodulators, immune correlates of protection, and clinical trials.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
